ArticleCancer research2009
Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Dissociation of Murine Mammary Gland and Tumor Tissues to Create Highly Viable Single-Cell Suspensions.Journal of visualized experiments : JoVE · 2026Article
- Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model.iScience · 2023Article
- Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.Frontiers in immunology · 2023Article
- A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors.Oncoimmunology · 2022Article
- Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.Cancer immunology, immunotherapy : CII · 2019Article
- Review
- Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.Cancer immunology research · 2015Article
- Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Oncoimmunology · 2015Article
- Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.PloS one · 2015Article
- Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.Cancer immunology, immunotherapy : CII · 2012Article
- Camouflage and sabotage: tumor escape from the immune system.Cancer immunology, immunotherapy : CII · 2011Review
- Genetic regulation of antibody responses to human epidermal growth factor receptor 2 in breast cancer.Human immunology · 2010Article
- Anti-HER2 vaccines: new prospects for breast cancer therapy.Cancer immunology, immunotherapy : CII · 2010Review
- Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.Cancer immunology, immunotherapy : CII · 2010Article
- Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.Cancer research · 2010Article
- Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Genetic regulation of immune reactivity to Her-2 vaccination and the consequent antitumor effect was tested in human Her-2 transgenic (Tg) mice of C57BL/6 (B6), BALB/c (BALB), and (B6x BALB) F1 (F1) background. Mice were electrovaccinated with Her-2 DNA with or without pretreatment with CD25 monoclonal antibody to remove CD25(hi) regulatory T cells. When CD25(+) T cells were intact, BALB Her-2 Tg mice were more responsive than the other two strains in both humoral and cellular immunities, and their tumor growth was significantly delayed. B6 Her-2 Tg mice responded poorly and F1 mice showed modest immune reactivity, but tumor growth did not change in either strain. Depletion of CD25(hi) T cells before vaccination significantly improved protection from tumor challenge in F1 Her-2 Tg mice. This was associated with elevated levels of Her-2 IgG1, IgG2a, and IgG2c antibodies, and some mice also showed IFN-gamma producing T-cell response. The same treatment induced modest improvement in B6 Her-2 Tg mice. In BALB Her-2 Tg mice, however, depletion of CD25(hi) T cells did not further improve antitumor efficacy. Although their Her-2-specific IgG1 and interleukin-5-secreting T cells increased, the levels of IgG2a and IFN-gamma-secreting T cells did not change. These results are the first to show genetic regulation of the response to a cancer vaccine and an unequal effect of removing CD25(hi) T cells on antitumor immunity. These results warrant individualized treatment plans for patients with heterogeneous genetic backgrounds and possibly differential intrinsic immune reactivity to tumor antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.